X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs BIOCON LTD - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD BIOCON LTD ORCHID PHARMA LTD/
BIOCON LTD
 
P/E (TTM) x -0.6 71.1 - View Chart
P/BV x 0.4 6.7 6.7% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 ORCHID PHARMA LTD   BIOCON LTD
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
BIOCON LTD
Mar-17
ORCHID PHARMA LTD/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs1941,162 16.7%   
Low Rs35483 7.3%   
Sales per share (Unadj.) Rs276.5194.6 142.1%  
Earnings per share (Unadj.) Rs-79.234.4 -230.2%  
Cash flow per share (Unadj.) Rs-43.548.3 -90.0%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.1 0.0%  
Book value per share (Unadj.) Rs53.9241.9 22.3%  
Shares outstanding (eoy) m70.45200.00 35.2%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.44.2 9.8%   
Avg P/E ratio x-1.423.9 -6.0%  
P/CF ratio (eoy) x-2.617.0 -15.5%  
Price / Book Value ratio x2.13.4 62.5%  
Dividend payout %02.9 0.0%   
Avg Mkt Cap Rs m8,067164,440 4.9%   
No. of employees `0002.89.2 30.3%   
Total wages/salary Rs m2,5277,470 33.8%   
Avg. sales/employee Rs Th6,956.14,213.9 165.1%   
Avg. wages/employee Rs Th902.5809.0 111.6%   
Avg. net profit/employee Rs Th-1,993.0745.2 -267.4%   
INCOME DATA
Net Sales Rs m19,47738,911 50.1%  
Other income Rs m4071,571 25.9%   
Total revenues Rs m19,88440,482 49.1%   
Gross profit Rs m1,1039,795 11.3%  
Depreciation Rs m2,5192,772 90.9%   
Interest Rs m5,227260 2,010.3%   
Profit before tax Rs m-6,2368,334 -74.8%   
Minority Interest Rs m20163 12.1%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1251,616 -7.7%   
Profit after tax Rs m-5,5806,881 -81.1%  
Gross profit margin %5.725.2 22.5%  
Effective tax rate %2.019.4 10.4%   
Net profit margin %-28.717.7 -162.0%  
BALANCE SHEET DATA
Current assets Rs m11,01440,477 27.2%   
Current liabilities Rs m32,06016,783 191.0%   
Net working cap to sales %-108.160.9 -177.5%  
Current ratio x0.32.4 14.2%  
Inventory Days Days9560 159.2%  
Debtors Days Days3483 40.5%  
Net fixed assets Rs m29,44045,073 65.3%   
Share capital Rs m7051,000 70.5%   
"Free" reserves Rs m2,04347,377 4.3%   
Net worth Rs m3,80048,377 7.9%   
Long term debt Rs m9,01821,082 42.8%   
Total assets Rs m46,51093,942 49.5%  
Interest coverage x-0.233.1 -0.6%   
Debt to equity ratio x2.40.4 544.6%  
Sales to assets ratio x0.40.4 101.1%   
Return on assets %-0.87.6 -10.0%  
Return on equity %-146.914.2 -1,032.5%  
Return on capital %-3.712.6 -29.6%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,51312,988 57.8%   
Fx outflow Rs m5,6497,899 71.5%   
Net fx Rs m1,8655,089 36.6%   
CASH FLOW
From Operations Rs m1,6826,400 26.3%  
From Investments Rs m-9,860-4,985 197.8%  
From Financial Activity Rs m6,644-1,775 -374.3%  
Net Cashflow Rs m-1,535-473 324.5%  

Share Holding

Indian Promoters % 32.3 40.4 80.0%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 4.6 8.4 54.8%  
FIIs % 3.3 10.7 30.8%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 19.9 277.9%  
Shareholders   84,811 109,995 77.1%  
Pledged promoter(s) holding % 54.9 0.0 137,300.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   SUN PHARMA  WYETH LTD  ABBOTT INDIA  UNICHEM LAB  DR. REDDYS LAB  

Compare ORCHID PHARMA LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Near Record High; Realty Stocks Bleed(Closing)

After opening the day on a strong note, share markets in India witnessed volatility during the last hour of trading session. However, they managed to end the day on a positive note.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Jan 18, 2018 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 8-QTR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS